Results 91 to 100 of about 9,804 (228)

Disrupting Viral Persistence: CRISPR/Cas9‐Based Strategies for Hepatitis B and C Treatment, and Challenges

Journal of Cellular and Molecular Medicine, Volume 30, Issue 1, January 2026.
ABSTRACT Hepatitis B and C viruses (HBV and HCV) remain among the leading causes of liver disease worldwide. Current antiviral drugs, such as nucleotide analogues (NAs), can reduce the replication of new HBV and HCV infections but cannot completely eliminate chronic infections.
Meng‐Fan Li, Akmal Zubair, Safa Wdidi, Shan He   +3 more
wiley   +1 more source

Interferon-inducible protein SCOTIN interferes with HCV replication through the autolysosomal degradation of NS5A [PDF]

, 2019
Hepatitis C virus (HCV) utilizes autophagy to promote its propagation. Here we show the autophagy-mediated suppression of HCV replication via the endoplasmic reticulum (ER) protein SCOTIN.
Eui-Cheol Shin, Min-Jung Kim, Nari Kim, Pil Soo Sung, Yong Chul Bae, Yoo, JY   +5 more
core   +1 more source

Health Benefits and Therapeutic Potential of Quercetin

Journal of Food Biochemistry, Volume 2026, Issue 1, 2026.
Quercetin, a polyphenolic compound prevalent in many fruits, vegetables, and other dietary sources, has attracted considerable interest due to its extensive health benefits. This review examines its diverse biological properties, particularly its antioxidant and anti‐inflammatory effects. The study integrates recent scientific findings to elucidate the
Mahendra Aryal, Kim Wei Chan
wiley   +1 more source

Recent Advancements in Known and Emerging Risk Factors of Hepatocellular Carcinoma

Cancer Medicine, Volume 14, Issue 21, November 2025.
ABSTRACT Background Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and a leading cause of cancer‐related deaths worldwide. Despite advancements in antiviral therapies for hepatitis B (HBV) and hepatitis C (HCV), HCC incidence continues to rise due to metabolic dysfunction‐associated steatotic liver disease (MASLD), obesity ...
Muhammad Masroor Hussain, Bi Feng, Ju‐Mei Wang, Ao‐Qiang Zhai, Fu‐yu Li, Hai‐jie Hu   +5 more
wiley   +1 more source

Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection

Annals of Hepatology, 2016
Background. Patient race and ethnicity have historically impacted HCV treatment response. This phase 3 study evaluated daclatasvir with peginterferon-alfa-2a/ribavirin (pegIFN alfa-2a/RBV) in treatment-naive black/African American (AA), Latino, and white
Maribel Rodriguez-Torres, Eric Läwitz, Bienvenido Yangco, Lennox Jeffers, Steven-Huy Han, Paul J. Thuluvath, Vinod Rustgi, Stephen Harrison, Reem Ghalib, John M. Vierling, Velimir Luketic, Philippe J. Zamor, Natarajan Ravendhran, Timothy R. Morgan, Brian Pearlman, Christopher O’Brien, Hicham Khallafi, Nikolaos Pyrsopoulos, George Kong, Fiona McPhee, Philip D. Yin, Eric Hughes, Michelle Treitel   +22 more
doaj   +1 more source

Small Molecule Targeting of Atypical p38 Protects Against Viral Infection

The FASEB Journal, Volume 39, Issue 20, 31 October 2025.
Targeting host signaling pathways offers a complementary strategy to direct‐acting antivirals. Small‐molecule modulators of atypical p38 block Hepatitis C virus replication and also inhibit Human Cytomegalovirus. By disrupting virus‐induced p38 activation, these compounds suppress viral RNA replication and protein expression, highlighting atypical p38 ...
Fredejah T. Royer, Jeremy C. Burton, Johnathan Burns, Megan G. Lloyd, Reuben Onwe, Jennifer F. Moffat, Neil J. Grimsey   +6 more
wiley   +1 more source

From Guidelines to Real‐Time Conversation: Expert‐Validated Retrieval‐Augmented and Fine‐Tuned GPT‐4 for Hepatitis C Management

Liver International, Volume 45, Issue 10, October 2025.
ABSTRACT Background and Aims Advances in artificial intelligence, particularly large language models (LLMs), hold promise for transforming chronic disease management such as Hepatitis C Virus (HCV) infection. This study evaluates the impact of retrieval‐augmented generation (RAG) and supervised fine‐tuning (SFT) on both open‐ended question answering ...
Mauro Giuffrè, Nicola Pugliese, Simone Kresevic, Milos Ajcevic, Francesco Negro, Massimo Puoti, Xavier Forns, Jean‐Michel Pawlotsky, Dennis L. Shung, Alessio Aghemo   +9 more
wiley   +1 more source

Partly 5` Untranslated Region (5` UTR)-Based Phylogenetic Analysis of Three Hepatitis C Virus Isolates From Jakarta, Indonesia: a Preliminary Study [PDF]

, 2014
Currently, we reported results of a nested PCR assay specific 5` UTR region of HCV genome that showed three different patterns of DNA fragments (single expected specific DNA band, single DNA band higher in size than an expected band, and multiple DNA ...
Rosilawati, M. L. (Maria), Yasmon, A. (Andi)   +1 more
core   +2 more sources

NSP7 Molecular Degrader Attenuates Coronaviral Infection Through the β‐TrCP1/FBXO5 Axis

Advanced Science, Volume 12, Issue 36, September 25, 2025.
Host E3 ligase FBXO5 as a key regulator that promotes K48‐linked ubiquitination and proteasomal degradation of SARS‐CoV‐2 NSP7, thereby suppressing viral replication. NSP7 ubiquitination is co‐regulated by β‐TrCP1 and TAF1. Small molecule BC24877 disrupts β‐TrCP1‐mediated degradation of FBXO5, stabilizing FBXO5 and enhancing NSP7 clearance ...
Yao Tong, Travis B. Lear, Ferhan Tuncer, John J. Villandre, Áine N. Boudreau, Bo Lin, Irene Alfaras, Jason R. Kennerdell, Daniel P. Camarco, Mads B. Larsen, Yun Hua, Yanwen Chen, Meigin E. Chandler, Ricardo Pineda, Simon M. Barratt‐Boyes, John W. Evankovich, Toren Finkel, Yuan Liu, Bill B. Chen   +18 more
wiley   +1 more source

Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C

International Journal of Hepatology, 2016
Hepatitis C virus (HCV) is estimated to affect up to 150 million people worldwide. Despite worldwide prevalence, treatment modalities prior to 2011 remained suboptimal, with low virologic response rates and intolerable side effect profiles.
Allison M. Bell, Jamie L. Wagner, Katie E. Barber, Kayla R. Stover   +3 more
doaj   +1 more source